ACAD Q4 2022 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$136M+4.4% YoY

Gross Profit

$134M98.2% margin

Operating Income

-$46M-33.7% margin

Net Income

-$42M-30.6% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+4.4%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$588M

Total Liabilities

$187M

Stockholders' Equity

$400M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$136M	$131M	+4.4%
Gross Profit	$134M	$128M	+4.6%
Operating Income	-$46M	-$45M	-3.1%
Net Income	-$42M	-$43M	+3.2%